QUTENZA

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Oct 28, 2010 → Sep 26, 2013

NCT ID

NCT01252160

About QUTENZA

QUTENZA is a approved stage product being developed by Astellas Pharma for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT01252160. Target conditions include Neuralgia, Postherpetic.

What happened to similar drugs?

7 of 17 similar drugs in Neuralgia, Postherpetic were approved

Approved (7) Terminated (3) Active (8)

✅GalcanezumabEli LillyApproved

🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3

✅Etoricoxib + PlaceboMerckApproved

✅pregabalinPfizerApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

🔄placebo + pregabalinPfizerPhase 3

🔄Pregabalin + placeboPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02171182	Pre-clinical	Completed	Jan 1, 2014	Aug 1, 2015	Post-operative Peripheral Neuropathic Pain
NCT01478607	Phase 3	Completed	Nov 1, 2011	Feb 1, 2014	Painful Diabetic Peripheral Neuropathy (PDPN)
NCT01252160	Approved	Completed	Oct 28, 2010	Sep 26, 2013	Neuralgia, Postherpetic

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	26
ASP8477 + Placebo	Astellas Pharma	Phase 2	35
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
E2007	Eisai	Phase 2/3	38
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Galcanezumab	Eli Lilly	Approved	43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	35
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
Cetuximab + Placebo	Merck	Phase 2	35
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
EMA401 + Placebo	Novartis	Phase 2	27
pregabalin	Pfizer	Approved	43
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43
2-weeks placebo then gabapentin + 1-week placebo then gabapentin	Pfizer	Pre-clinical	26